Clinical Trials · NCT02058160
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Sanofi
- Enrollment
- 736
- Start date
- Jan 2014
- Locations
- 236 sites, 18 countries
- Primary endpoint
- Change in Glycated Hemoglobin (HbA1c) From Baseline to Week 30